Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
WEST LAFAYETTE, Ind., Nov. 09, 2017 -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Jefferies 2017 London Healthcare Conference on Wednesday, Nov. 15, 2017, at 8:40 a.m. GMT.
A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company’s agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate-specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
